IHC analysis the changes of CD25+ and NK cell in SLN with breast cancer

Jian-jun HE,Yu REN,Yong-ping HUO,Yun-feng ZHANG,Ke WANG,Wu-ke CHEN
DOI: https://doi.org/10.3969/j.issn.1005-8982.2007.13.015
2007-01-01
Abstract:[Objective] To Analysis dynamically the changes of CD25+ and NK Cell in SLN with breast cancer. [Methods] Micrometastasis of SLNs was observed in 12 patients through immunohistochemical methods with CK19 monoantibody. We randomly chosed 9 patients from none-metastasis, and 10 patients from metastasis. Together, 82 SLNs were examined in all patients (31 cases). Then we tested all samples once more based on routine pathological diagnosis and immunohistochemical results with CK19 monoantibody in order to determine the status of SLNs. Monoantibody of CD25 as well as CD56 and SABC immunohistochemical methods were employed to determine the total number of lymphocytes and dye positive cells in five high scope-fields. The percentage of positive-dye cells was calculated out based on the average number of them. [Results] Among all 82 SLNs, none-metastasis was found in 35 SLNs, micrometastasis in 20 SLNs and metastasis in 27 SLNs, respectively. The ratio of CD25+ cells account for total lymphocytes was not different sinificantly between none-metastasis and micrometastasis groups (P =0.260) as well as different between micro-metastasis and metastasis groups (P <0.01). the ratio of CD56+ cells didn′t exhibit significantly difference among three groups (F =0.755, P >0.05), neither did the average. [Conclusion] The number of CD25+ cells would be obviously changed by none-metastasis and micrometastasis status; but be significantly increased by HE-metastasis in SLNs with breast cancer. The number of NK cells would be obviously changed by any metastasis status in SLNs.
What problem does this paper attempt to address?